UNITED STATES
           SECURITIES AND EXCHANGE COMMISSION

                  Washington, D.C. 20549
                       FORM 10-QSB

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR
     15(d)OF THE SECURITIES AND EXCHANGE ACT OF
     1934 For the Quarter ended December 31, 2002

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d)
     OF THE EXCHANGE ACT
     For the transition period         to
                               ------    ------

       Commission file number -  000-28787

              Micro Laboratories, Inc.
    (Exact name of Registrant as specified
             in its charter)
<TABLE>

                         <c>                           <c>
  NEVADA                                            05-049-4587
 (State or other (Primary Standard Industrial    (I.R.S. Employer
jurisdictions      Classification Code Number)  Identification number)
of incorporation
or organization

                      29 Lakeside Drive,
                   Johnston, Rhode Island               02919
          (Address of principal executive offices)    (Zip Code)
</TABLE>
       Telephone:  (401) 949-3562
   (Registrant's telephone number,
     including area code)

Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and
Exchange Act of 1934 during the preceding twelve months (or such
shorter period that the Registrant was required to file such reports),
and (2) has been subject to file such filing requirements for the past
thirty days.

Yes    x      No
    ------       ------
Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the close of the period covered by this
report:

    49,957,500 Shares of Common Stock
               (Title of Class)

Transitional Small Business Disclosure Format
    Yes           No    x
       -------       -------



<PAGE>2
             Micro Laboratories, Inc.

PART I:  Financial Information

         ITEM 1 - Financial statements

         ITEM 2 - Management's' discussion and
                    analysis of financial
                    condition and results of
                    operations

         ITEM 3 - Controls and Procedures

PART II:      Other Information

         ITEM 6 - Exhibits and Reports on Form 8-K








<PAGE>3

                  PART I
         Item 1. Financial Statements:

                   Micro Laboratories, Inc.
                (A Development Stage Company)
                        Balance Sheet
                         (Unaudited)
                            ASSETS
<TABLE>
<CAPTION>
                                                                December 31,
                                                                   2002
                                                                ------------

                                                                <c>
Current assets:
  Cash                                                           $     1,009
  Prepaid expenses                                                     3,000
                                                                 -----------
      Total current assets                                             4,009

Property and equipment, net of accumulated
  depreciation of $36,924                                             16,167

Other assets                                                           1,600
                                                                 -----------
Total assets                                                     $    21,776

             LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
  Accounts payable                                               $   379,492
  Accrued legal settlement                                            65,000
  Loans from related parties                                         769,073
                                                                 -----------
      Total current liabilities                                    1,213,565


 Common stock, $.001 par value,
  50,000,000 shares authorized, 49,597,500
  shares issued and outstanding                                       49,958
 Additional paid in capital                                        1,531,345
 (Deficit) accumulated during
  development stage                                               (2,773,092)
                                                                 -----------
                                                                  (1,191,789)
                                                                 -----------
                                                                 $    21,776
</TABLE>


      See accompanying notes to financial statements.




<PAGE>4

             Micro Laboratories, Inc.
          (A Development Stage Company)
             Statements of Operations
Three Months and Nine Months Ended December 31, 2002 and 2001
For the Period From Inception (March 28, 2000) to December 31, 2002
                   (Unaudited)
<TABLE>
<CAPTION>
                                                                        Period From
                             Three Months Ended    Nine Months Ended    Inception To
                                December 31,         December 31,       December 31,
                           2002             2001  2002           2001        2002
                          ----------------------- -------------------   -------------

                        <c>              <c>    <c>         <c>            <c>
 Sales                   $   1,840       $     -  $   6,294    $     -     $  6,294

 Operating expenses:
  Advertising expense          475         3,000      7,475      3,000      486,731
  Professional fees          1,050         5,500     19,450      9,150      402,949
  Consulting                     -       534,400          -    534,400      692,805
  Research and development       -             -          -          -      256,203
  Investor services              -             -          -          -      174,810
  Depreciation expense       1,881             -      5,643      2,984       39,970
  Office expenses            2,081         1,475      5,386      1,475       22,411
  Telephone expense          1,015         2,239      4,989      5,898       54,236
  Other expenses             1,997         4,697     10,151     20,378      456,480
                          --------      --------   --------     ------    ---------
                             8,500       551,311     53,095    577,285    2,586,596
                          --------      --------   --------    -------    ---------
(Loss) from operations      (6,659)     (551,311)   (46,800)  (577,285)  (2,580,301)

Other income (expense)
  Legal settlement               -             -          -          -      (65,000)
  Loss on sale of asset          -             -          -          -       (8,653)
  Write-off of obsolete
     inventories                 -             -          -          -      (27,572)
  Loss on impairment of
     assets                      -             -          -          -      (98,220)
  Interest income                -             -          -          -        6,654
                           -------      --------   --------    -------    ---------
                                 -             -          -          -     (192,791)
                           -------      --------   --------    -------    ---------
Net (loss)                 $(6,659)    $(551,311)  $(46,800) $(577,285) $(2,773,092)
                           =======     =========   ========  =========  ===========
Per share information:
Basic and diluted (loss)
  per common share         $     -     $   (0.01)  $      -  $   (0.01)
                           =======     =========   ========  =========
</TABLE>


 See accompanying notes to financial statements.



<PAGE>5
                  Micro Laboratories, Inc.
                (A Development Stage Company)
                  Statements of Cash Flows
        Nine Months Ended December 31, 2002 and 2001
For the Period From Inception (March 28, 2000) to December 31, 2002
                         (Unaudited)
<TABLE>
<CAPTION>
                                                                              Period From
                                                   Nine Months Ended         Inception To
                                                       December 31,          December 31,
                                                 2002              2001         2002
                                                 ----------------------      ------------

                                               <c>               <c>          <c>
Net income (loss)                               $ (46,800)     $  (577,285) $ (2,773,092)
  Adjustments to reconcile net income to net
   cash provided by operating activities:
   Services provided for common stock                   -          527,000       945,335
   Depreciation and amortization                    5,643            2,984        52,072
   Loss on sale of equipment                            -                -         8,653
   Asset impairment losses                              -                -       109,945
Changes in assets and liabilities:
(Increase) decrease in:
   Prepaid expenses                                     -                -       (20,033)
   Inventory                                            -                -       (10,007)
   Deposits                                             -                -        26,440
Increase (decrease) in:
   Accounts payable                                13,304            1,000       379,492
   Accrued legal settlement                             -                -        65,000
                                                ---------       ----------   -----------
  Total adjustments                                18,948          530,984     1,556,898
                                                ---------       ----------   -----------
  Net cash provided by (used in)
   operating activities                           (27,853)         (46,301)   (1,216,195)

Cash flows from investing activities:
   Acquisition of property & equipment                  -                -       (79,142)
   Acquisition of formulas & trademarks                 -                -       (75,750)
   Proceeds from sale of equipment                      -                -         9,825
   Loans to related parties                             -                -       (27,664)
                                                ---------       ----------    ----------
  Net cash provided by (used in)
   financing activities                                 -                -      (172,731)

Cash flows from financing activities:
   Common stock sold for cash                           -                -       593,198
   Loans from related parties                      28,862           46,301       796,737
                                                ---------       ----------    ----------
  Net cash provided by (used in)
   financing activities                            28,862           46,301     1,389,935
                                                ---------       ----------    ----------



<PAGE>6

Increase (decrease) in cash                         1,009                -         1,009
Cash and cash equivalents,
 beginning of period                                    -                -             -
                                                ---------        ---------    ----------
Cash and cash equivalents,
 end of period                                  $   1,009        $       -    $    1,009
</TABLE>

See accompanying notes to financial statements.




<PAGE>7

Micro Laboratories, Inc.
Notes to Unaudited Financial Statements
December 31, 2003

Basis of presentation

The accompanying unaudited financial statements have been prepared in
accordance with generally accepted accounting principles for interim
financial information and with the instructions incorporated in
Regulation SB of the Securities and Exchange Commission.  Accordingly,
they do not include all of the information and footnotes required by
generally accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments (consisting
of normal recurring adjustments and accruals) considered necessary for
a fair presentation have been included.

The results of operations for the periods presented are not necessarily
indicative of the results to be expected for the full year. The
accompanying financial statements should be read in conjunction with
the Company's financial statements for the year ended March 31, 2002
included in the Company's filing on Form 10-K.

Basic loss per share was computed using the weighted average number of
common shares outstanding.

The Company had an outstanding advance balance due to related parties
of $769,013 December 31, 2002.  The advance increased by $28,862 during
the nine months ended December 31, 2002.




<PAGE>8
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

Trends and Uncertainties. Demand for Micro's products will be dependent
on, among other things, general economic conditions, which are cyclical
in nature. Inasmuch as a major portion of Micro's activities is the
receipt of revenues from the sale of its products, Micro's business
operations may be adversely affected by its competitors and prolonged
recessionary periods.

Capital and Source of Liquidity. Micro currently has no material
commitments for capital expenditures.

For the nine months ended December 31, 2002 and 2001, Micro did not
pursue any investing activities.

For the nine months ended December 31, 2002, Micro received loans from
related parties of $28,862 resulting in net cash provided by financing
activities of $28,862.

For the nine months ended December 31, 2001, Micro received loans from
related parties of $46,201 resulting in net cash provided by financing
activities of $46,201.

On a long-term basis, liquidity is dependent on commencement of
operations as discussed above, receipt of revenues, additional
infusions of capital and debt financing.

Micro believes that additional capital and debt financing in the short
term will allow Micro to increase its marketing and sales efforts and
become a fully operational corporation thereafter resulting in
increased revenue and greater liquidity in the long term. However,
there can be no assurance that Micro will be able to obtain additional
equity or debt financing in the future, if at all.

Results of Operations. Micro is accurately classified as a development
stage corporation and has conducted startup and development operations
that include:
   - completed photo shoots, created corporation logos, brochures,
sales literature, product labels and packaging design, UPCs
   - prepared the product line of six items for distribution roll out



<PAGE>9

   - completed negotiations with three large distributors to include
west coast, mid west, and New England to represent and sell the
Company's product lines to national chains.

Micro received revenues of $6,294 for the nine months ended December
31, 2002. For the nine months ended December 31, 2002, Micro had a net
loss of $(46,800).   Operating expenses were $46,800 and consisted of
advertising expense of $7,475, professional fees of $19,450,
depreciation expense of $5,643, office expenses of $4,386, telephone
expense of $4,989 and other expenses of $10,151.

Micro received no revenues for the nine months ended December 31, 2001.
For the nine months ended December 31, 2001, Micro had a net loss of
$(577,285).   Operating expenses were $577,285 and consisted of
advertising expense of $3,000, professional fees of $9,150, consulting
fees of $534,400, depreciation expense of $2,984, telephone expense of
$5,989 and other expenses of $20,378.

Plan of Operation. Micro is in the development stage and has not
conducted any significant operations to date or received any material
operating revenues. Micro has experienced problems, delays, expenses
and difficulties sometimes encountered by an enterprise in Micro's
stage of development, many of which are beyond Micro's control. These
include, but are not limited to, unanticipated problems relating to
additional costs and expenses that may exceed current estimates,
competition, product development and acceptance; and lack of
distribution channels.

Micro has a working capital deficiency of $1,189,000 and is arguably
delinquent on some of its obligations.   Micro intends to market its
products and services utilizing cash made available from the private
sale of its securities and operations.

Micro's management is currently looking for an acquisition candidate
and is of the opinion that the proceeds of the sales of its securities
and future revenues will not be sufficient to pay its expenses for the
next twelve months. Advances from its president will be required to
continue the minimal operations of Micro.



<PAGE>10

Item 3. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the participation of our
chief executive officer and chief financial officer, conducted an
evaluation of our "disclosure controls and procedures" (as defined in
Securities Exchange Act of 1934 (the "Exchange Act") Rules 13a-14(c))
within 90 days of the filing date of this quarterly report on Form
10QSB (the "Evaluation Date").  Based on their evaluation, our chief
executive officer and chief financial officer have concluded that as of
the Evaluation Date, our disclosure controls and procedures are
effective to ensure that all material information required to be filed
in this quarterly report on Form 10QSB has been made known to them in a
timely fashion.

Changes in Internal Controls

There have been no significant changes (including corrective actions
with regard to significant deficiencies or material weaknesses) in our
internal controls or in other factors that could significantly affect
these controls subsequent to the Evaluation Date set forth above.







<PAGE>11

                    PART II
               OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS.

    Not applicable.

ITEM 2.  CHANGES IN SECURITIES.

    Not applicable.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

    Not applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF
          SECURITY HOLDERS.

    Not applicable.

ITEM 5.  OTHER INFORMATION.

    Not applicable.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.

(a)  Exhibit 99 - Certification pursuant to
                  18 U.S.C. Section 1350

    (b)  Not applicable.




               SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.


/s/ Robert Thistle
----------------------------
Robert Thistle, President


January 31, 2003



<PAGE>12

               CERTIFICATIONS

I, Robert Thistle, certify that:

1.   I have reviewed this quarterly report on Form 10QSB of Micro
Laboratories, Inc.

2.   Based on my knowledge, the quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to
the period covered by this quarterly report;

3.   Based on my knowledge, the financial statements, and other
financial information included in this quarterly report, fairly
present, in all material respects, the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods
presented in this quarterly report;

4.   The registrant's other certifying officers and I are responsible
for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
we have:

(a)  designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this quarterly report
is being prepared;

(b)   evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the filing
date of this quarterly report (the "Evaluation Date"); and

(c)   presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

5.   The registrant's other certifying officers and I have disclosed,
based on our most recent evaluation, to the registrant's auditors and
the audit committee of the registrant's board of directors (or persons
performing the equivalent function):

(a)   all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's ability
to record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in
internal controls; and

 (b)   any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's
internal controls; and



(6)   The registrant's other certifying officers and I have indicated
in this quarterly report whether or not there were significant changes
in internal controls or in other factors that could significantly
affect internal controls subsequent to the date of our most recent
evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.

Date:  January 31, 2003

/s/Robert Thistle
--------------------------
Robert Thistle
Chief Executive Officer
Chief Financial Officer